Literature DB >> 12163330

Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors.

Shine Chang1, Xifeng Wu, He Yu, Margaret R Spitz.   

Abstract

As evidence builds for cancer risk associated with insulin-like growth factors (IGFs) and their binding proteins (BPs), capitalizing on such associations for cancer prevention requires identifying the determinants of IGF levels. We measured plasma IGF-I, IGF-II, and IGF BP-3 in a cross-section of 210 men and 171 postmenopausal women enrolled in research as healthy controls. Using linear regression adjusted for age and ethnicity, we evaluated associations between IGF and IGF BP levels and gender, height, body mass index (BMI), smoking, caloric intake, physical activity, and reproductive factors. As expected, women using hormone replacement therapy (HRT) recently had significantly lower IGF-I levels than nonusers. Overall, IGF-I and IGF BP-3 levels did not differ by gender, although men had significantly higher molar ratios of IGF-I to IGF BP-3 and lower plasma IGF-II than women without recent HRT use. For men, BMI was a better predictor of IGF-I levels than height, whereas for women, height was more important. Lower IGF-II levels for both genders were associated with higher BMI and lower physical activity. Lower physical activity was associated with lower IGF BP-3 levels among men. Miscarriage number and menopausal age were positively associated with IGF BP-3 levels. HRT use strongly depressed IGF-I levels among smokers, and additional analysis revealed no remarkable associations. Caloric intake was negatively associated with IGF-I levels among men. Results for ratios of IGF-I and IGF-II to IGF BP-3 generally reflected those for IGF-I and IGF-II levels, respectively. In conclusion, whereas some traditional cancer risk factors were associated with IGF levels, altogether, they accounted for <15% of the total variability in plasma levels for each IGF, suggesting that other factors influence IGF levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163330

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  17 in total

1.  Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors.

Authors:  Melinda L Irwin; Anne McTiernan; Leslie Bernstein; Frank D Gilliland; Richard Baumgartner; Kathy Baumgartner; Rachel Ballard-Barbash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-12       Impact factor: 4.254

2.  Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community.

Authors:  Carolyn S P Lam; Ming-Huei Chen; Sean M Lacey; Qiong Yang; Lisa M Sullivan; Vanessa Xanthakis; Radwan Safa; Holly M Smith; Xuyang Peng; Douglas B Sawyer; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-04-08       Impact factor: 8.311

3.  Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival.

Authors:  Adetunji T Toriola; Mark Ziegler; Yize Li; Michael Pollak; Rachael Stolzenberg-Solomon
Journal:  Ann Surg Oncol       Date:  2017-07-05       Impact factor: 5.344

4.  Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review.

Authors:  Ming Yin; Xiaoxiang Guan; Zhongxin Liao; Qingyi Wei
Journal:  Am J Transl Res       Date:  2009-01-30       Impact factor: 4.060

Review 5.  Physical activity before and after diagnosis of colorectal cancer: disease risk, clinical outcomes, response pathways and biomarkers.

Authors:  David J Harriss; N Tim Cable; Keith George; Thomas Reilly; Andrew G Renehan; Najib Haboubi
Journal:  Sports Med       Date:  2007       Impact factor: 11.136

6.  Anthropometric correlates of insulin-like growth factor 1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels by race/ethnicity and gender.

Authors:  Jessica M Faupel-Badger; David Berrigan; Rachel Ballard-Barbash; Nancy Potischman
Journal:  Ann Epidemiol       Date:  2009-12       Impact factor: 3.797

7.  Predictors of variation in serum IGF1 and IGFBP3 levels in healthy African American and white men.

Authors:  Cathrine Hoyo; Janet Grubber; Wendy Demark-Wahnefried; Bruce Lobaugh; Amy S Jeffreys; Steven C Grambow; Jeffrey R Marks; Temitope O Keku; Phillip J Walther; Joellen M Schildkraut
Journal:  J Natl Med Assoc       Date:  2009-07       Impact factor: 1.798

8.  Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.

Authors:  Marian L Neuhouser; Jeannette Schenk; Yoon Ju Song; Catherine M Tangen; Phyllis J Goodman; Michael Pollak; David F Penson; Ian M Thompson; Alan R Kristal
Journal:  Prostate       Date:  2008-09-15       Impact factor: 4.104

9.  Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database.

Authors:  Jayakrishnan Jayachandran; Lionel L Bañez; William J Aronson; Martha K Terris; Joseph C Presti; Christopher L Amling; Christopher J Kane; Stephen J Freedland
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

10.  Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability.

Authors:  Helen Swede; Thomas E Rohan; Herbert Yu; Joseph C Anderson; Richard G Stevens; Jane Brokaw; Joel Levine; Bruce M Brenner; Carl D Malchoff; Valerie B Duffy; Devon C Pleau; Daniel W Rosenberg
Journal:  Cancer Causes Control       Date:  2008-12-09       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.